• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    11/12/24 4:50:36 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XLO alert in real time by email
    SC 13G/A 1 rocksprings-xlo093024a2.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    Schedule 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*



    Xilio Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    98422T100

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  98422T100
     Schedule 13G/A
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital Management LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    3,003,259
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    3,003,259
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    3,003,259
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    6.83%
    12
    TYPE OF REPORTING PERSON
     
    IA

     

     


     

    CUSIP No.  98422T100
     Schedule 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    3,003,259
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    3,003,259
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    3,003,259
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    6.83%
    12
    TYPE OF REPORTING PERSON
     
    OO; HC

     

     


     

    CUSIP No.  98422T100
     Schedule 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital Master Fund LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,600,625
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,600,625
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,600,625
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.92%
    12
    TYPE OF REPORTING PERSON
     
    PN

     

     
     

     

    CUSIP No.  98422T100
     Schedule 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Xilio Therapeutics, Inc. (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices

    828 Winter Street, Suite 300

    Waltham, Massachusetts 02451

    Item 2.(a) Name of Person Filing

    This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

    i. Rock Springs Capital Management LP (“RSCM”);

    ii. Rock Springs Capital LLC (“RSC”); and

    iii. Rock Springs Capital Master Fund LP (“Master Fund”).

     

    This Statement relates to Shares (as defined herein) held directly by the Master Fund, which is a Cayman Island exempted limited partnership, and Four Pines Master Fund LP (“Four Pines”), which is a Cayman Islands exempted limited partnership, and indirectly held by RSCM, a Delaware limited partnership, and RSC, a Delaware limited liability company. RSCM serves as the investment manager to each of the Master Fund and Four Pines. RSC is the general partner of RSCM.

    (b) Address of Principal Business Office, or, if none, Residence

    Rock Springs Capital Management LP and Rock Springs Capital LLC

    650 South Exeter, Suite 1070

    Baltimore, MD 21202

     

    Rock Springs Capital Master Fund

    c/o Walkers Corporate Limited

    190 Elgin Avenue

    George Town, Grand Cayman, KY1-9008, Cayman Islands

     

    (c) Citizenship

    Rock Springs Capital Management LP - Delaware

    Rock Springs Capital LLC - Delaware

    Rock Springs Capital Master Fund LP - Cayman Islands

     (d) Title of Class of Securities

    Common Stock, par value $0.0001 per share (the “Shares”)

     (e) CUSIP No.:

    98422T100

     
     

     

    CUSIP No.  98422T100
     Schedule 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

     
     

     

    CUSIP No. 98422T100
     Schedule 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    As of September 30, 2024, each of RSCM and RSC may be deemed to be the beneficial owners of 3,003,259 Shares, which amount includes 2,600,625 Shares directly beneficially owned by the Master Fund, and 402,634 Shares directly beneficially owned by Four Pines. The percent of class is determined by dividing the number of Shares beneficially owned by the Reporting Persons by 43,952,491 as reported on the Issuer’s Form 10-Q filed on August 8, 2024.

    (a) Amount beneficially owned:

    Rock Springs Capital Management LP: 3,003,259

    Rock Springs Capital LLC: 3,003,259

    Rock Springs Capital Master Fund LP: 2,600,625

     

    (b) Percent of class:

    Rock Springs Capital Management LP: 6.83%

    Rock Springs Capital LLC: 6.83%

    Rock Springs Capital Master Fund LP: 5.92%

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (ii) Shared power to vote or to direct the vote:

    Rock Springs Capital Management LP: 3,003,259

    Rock Springs Capital LLC: 3,003,259

    Rock Springs Capital Master Fund LP: 2,600,625

     

    (iii) Sole power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (iv) Shared power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 3,003,259

    Rock Springs Capital LLC: 3,003,259

    Rock Springs Capital Master Fund LP: 2,600,625

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    See disclosure in Items 2 and 4 hereof. Certain funds listed in Item 2(a) are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Please see response to Item 2.

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     
     
    CUSIP No.  98422T100
     SCHEDULE 13G
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 12, 2024

     

     

     

    Rock Springs Capital Management LP

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

      Rock Springs Capital LLC
           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

     

    Rock Springs Capital Master Fund LP

    By: Rock Springs Capital Management LP, Investment Manager

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member
       

     

     

     
     
    CUSIP No. 98422T100
     SCHEDULE 13G
    Page 9 of 9 Pages

     

     

    JOINT FILING AGREEMENT

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Date: November 12, 2024

     

     

     

    Rock Springs Capital Management LP

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

      Rock Springs Capital LLC
           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

     

    Rock Springs Capital Master Fund LP

    By: Rock Springs Capital Management LP, Investment Manager

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

     

     

     

     

     

     

    Get the next $XLO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XLO

    DatePrice TargetRatingAnalyst
    8/6/2025$2.00Outperform
    Leerink Partners
    12/21/2022$7.00Buy
    Chardan Capital Markets
    1/10/2022$36.00Buy
    HC Wainwright & Co.
    11/16/2021$40.00Buy
    Guggenheim
    11/16/2021$31.00Outperform
    Raymond James
    11/16/2021Outperform
    Cowen & Co.
    11/16/2021$32.00Overweight
    Morgan Stanley
    More analyst ratings

    $XLO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

    Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy On track with plans to nominate first development candidates for wholly owned masked T cell engager programs in second half of 2025 $121.6 million in cash and cash equivalents as of June 30, 2025, with anticipated cash runway through end of third quarter of 2026 WALTHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-o

    8/14/25 7:30:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

    CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also currently serves as Chief Executive Officer of Timberlyne Therapeutics, a clinical-stage company focused on the development and commercialization of transformational therapies for autoimmune diseases. "Da

    8/4/25 8:03:00 AM ET
    $CPRX
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective August 1, 2025, the company granted non-qualified stock options to purchase 134,000 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $0.65 per share, which is equal to the closing price of the company's common stock on August 1, 2025. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stoc

    8/1/25 4:30:00 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shannon James Samuel bought $48,085 worth of shares (70,000 units at $0.69) (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:57:19 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Russo Rene bought $24,680 worth of shares (36,289 units at $0.68), increasing direct ownership by 15% to 281,172 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:56:47 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by PRESIDENT AND CEO Russo Rene

    4/A - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:55:49 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Xilio Therapeutics with a new price target

    Leerink Partners initiated coverage of Xilio Therapeutics with a rating of Outperform and set a new price target of $2.00

    8/6/25 7:25:30 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Xilio Therapeutics with a new price target

    Chardan Capital Markets initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $7.00

    12/21/22 7:57:28 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Xilio Therapeutics with a new price target

    HC Wainwright & Co. initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $36.00

    1/10/22 6:12:33 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    SEC Filings

    View All

    $XLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Xilio Therapeutics Inc.

    SCHEDULE 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    8/14/25 4:42:16 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Xilio Therapeutics Inc.

    10-Q - Xilio Therapeutics, Inc. (0001840233) (Filer)

    8/14/25 8:08:35 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

    8/14/25 7:35:34 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Shannon James Samuel bought $48,085 worth of shares (70,000 units at $0.69) (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:57:19 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Russo Rene bought $24,680 worth of shares (36,289 units at $0.68), increasing direct ownership by 15% to 281,172 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:56:47 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gilead Sciences, Inc. bought $1,830,377 worth of shares (1,759,978 units at $1.04), increasing direct ownership by 24% to 9,105,451 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    12/19/24 4:19:34 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Financials

    Live finance-specific insights

    View All

    Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

    Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended anticipated cash runway into the first quarter of 2026 Company to host investor conference call and webcast today at 8:30 am ET WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane antigen (PSMA), claudi

    2/12/25 7:35:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

    Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging X

    2/12/25 7:33:00 AM ET
    $ABBV
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

    Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am ESTNORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's p

    2/12/25 7:30:00 AM ET
    $ABBV
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Leadership Updates

    Live Leadership Updates

    View All

    Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

    CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also currently serves as Chief Executive Officer of Timberlyne Therapeutics, a clinical-stage company focused on the development and commercialization of transformational therapies for autoimmune diseases. "Da

    8/4/25 8:03:00 AM ET
    $CPRX
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

    WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company's board of directors. "Tunde is an accomplished leader with a strong track record of successfully developing novel therapies across a broad range of therapeutic areas, including several important cancer immunotherapies for anti-CTLA-4, PD-1 and T-cell engager through all stages of development, and I am thrilled to welcome him to the board," said Paul Clancy, chair of the board of dire

    6/10/25 4:30:00 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

    Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T cell engager programs in novel ATACR and SEECR formats for PSMA, CLDN18.2 and STEAP1 Announced collaboration with AbbVie in the first quarter of 2025 to develop novel tumor-activated, antibody-based immunotherapies, including masked T cell engagers WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipe

    3/11/25 7:30:58 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 5:44:28 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 4:30:23 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/12/24 4:50:36 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care